SCHEDULE: FMR LLC Reports 9.7% Stake in Avalo Therapeutics

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 9.7% of Avalo Therapeutics' common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, indicating their beneficial ownership of 5,100,216 shares of Avalo Therapeutics Inc. common stock.
• This holding represents 9.7% of the total outstanding common stock as of June 30, 2026.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is identified as an investment adviser (IA).
• The filing confirms that no single other person's interest in Avalo Therapeutics' common stock exceeds five percent.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial performance data.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, potentially indicating confidence in the company's long-term prospects.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• The filing does not contain any new financial performance data, operational updates, or forward-looking guidance, limiting insights into the company's current health or future trajectory.

Risks

• The concentration of ownership by a single entity could lead to significant influence over corporate decisions, which may or may not align with the interests of all shareholders.
• Dependence on the investment strategies and decisions of FMR LLC and Abigail P. Johnson.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Avalo Therapeutics' future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. The healthcare and biotechnology sectors, where Avalo Therapeutics operates, often see substantial investment from large asset managers like FMR LLC.

Stakeholder Impact

• Shareholders: Increased institutional ownership may signal stability or potential for future strategic shifts. The concentration of ownership by FMR LLC could influence corporate governance decisions.
• Management: May face increased scrutiny or influence from a significant institutional shareholder.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Continued monitoring of FMR LLC's and Abigail P. Johnson's beneficial ownership in Avalo Therapeutics.

Key Dates

Keywords

Avalo Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser